Inhibition of iNKT Cells by the HLA-G-ILT2 Checkpoint and Poor Stimulation by HLA-G-Expressing Tolerogenic DC

Cited by papers we hold 1

• Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial · 2022
  Corrected

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.